National Health and Medical Research: Towards a functional cure for Hepatitis B Virus: exploiting lessons from HBV-HIV co-infection (COMMIT Study)

Project Timeline

2018 – 2022

Hepatitis B virus (HBV) infection can be treated, but therapy is usually lifelong and has side effects, so a cure for HBV is a critical endpoint. This study examines the key steps to HBV cure in the setting of HIV-HBV co-infection, where rates of development of antibodies against HBV after starting HBV treatment are higher than in people with HBV alone starting treatment. In Asia both HBV and HIV are common so this provides a unique opportunity to study HBV. We will investigate how an effective immune response against the two main HBV proteins is developed. If we can understand how the immune response works against HBV, this could be used to develop new therapies towards a cure for HBV.

External Links


Other Clinical Research

Strategic Timing of Anti-Retroviral Treatment (START Study)
The START trial was designed to address the question: In HIV-1 (subsequently referred to as HIV) infected asymptomatic participants with a CD4+ count greater than 500 cells/mm3, is immediate use...
Making Drug Treatment Work: Opportunities and Challenges Towards an Evidence and Rights-Based Approach
Compulsory drug detention centers (CDDCs) are common throughout Asia. However, medical treatments for substance use disorders, such as opioid agonist treatment (OAT), are generally unavailable in these settings. In this...
Dolutegravir and Darunavir Evaluation in Adults Failing Therapy (D²EFT)
First-line antiretroviral regimens are safe, effective and easily administered (one pill taken once daily). Even so, the annual failure rate is around 10-15% of treated patients. Second-line regimens have a...